-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Capricor Therapeutics, Raises Price Target to $60

Benzinga·12/03/2025 19:05:51
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price target from $24 to $60.